Kamada Ltd. — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · Israel
Last price 7.95 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 451.69M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Details
| Name | Kamada Ltd. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 462 |
| Founded | 1990 |
| Ceo | Amir London |
| Country | Israel |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | IL0010941198 |
| Cusip | M6240T109 |
| Cik | 0001567529 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Amir London | Chief Executive Officer |
| Chaime Orlev | Chief Financial Officer |
| Eran Nir | Chief Operating Officer |
| Jon R. Knight | Vice President of US Commercial Operations |
| Boris Gorelik | Vice President of Business Development and Strategic Programs |
| David Tsur | Co-Founder and Independent Deputy Chairman of the Board |
| Nir Livneh B.A., L.L.B. | Vice President, General Counsel and Corporate Secretary |
| Hanni Neheman | Vice President of Marketing and Sales |
| Liron Reshef | Vice President of Human Resources |
| Shavit Beladev | Vice President of Kamada Plasma |
Contact
| Address | 2 Holzman Street, Science Park, Rehovot, 7670402, Israel |
| Phone | 972 8 940 6472 |
| Website | https://www.kamada.com |